Adaptive Biotechnologies Corporation announced preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025. Total revenue for the fourth quarter was approximately $72 million, and for the full year, approximately $277 million, representing increases of 51% and 55%, respectively, over the corresponding periods in 2024. The company’s MRD (minimal residual disease) revenue for the fourth quarter and full year 2025 was approximately $62 million and $212 million, increasing 54% and 46%, respectively, compared to 2024. Excluding MRD regulatory milestone revenue, MRD revenue for the full year grew 45%. clonoSEQ test volume increased 43% to about 30,000 tests in the fourth quarter of 2025 and totaled approximately 105,600 tests for the year, up 39% compared to 2024. Cash, cash equivalents, and marketable securities were approximately $227 million as of December 31, 2025. The company plans to release complete fourth quarter and full year 2025 financial results during its earnings call in February 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-009840), on January 12, 2026, and is solely responsible for the information contained therein.